Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
索托拉西布联合帕尼单抗与研究者选择的方案治疗化疗难治性KRAS G12C突变型结直肠癌的III期CodeBreakK 300研究的总生存期分析
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-02026
Pietrantonio, Filippo; Salvatore, Lisa; Esaki, Taito; Modest, Dominik Paul; Lopez-Bravo, David Paez; Taieb, Julien; Karamouzis, Michalis V; Ruiz-Garcia, Erika; Kim, Tae Won; Kuboki, Yasutoshi; Meriggi, Fausto; Cunningham, David; Yeh, Kun-Huei; Chan, Emily; Chao, Joseph; Tran, Qui; Cremolini, Chiara; Fakih, Marwan